BC-DXI-843

BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer[1].

Product Specifications

CAS Number

[2421117-98-6]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Aminoacyl-tRNA Synthetase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bc-dxi-843.html

Concentration

10mM

Purity

99.76

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2

Molecular Formula

C28H26N4O4S2

Molecular Weight

546.66

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Aneesh Sivaraman, et al. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J Med Chem. 2020 May 28;63 (10) :5139-5158.